Orbimed

Portfolio Companies 2026 for Orbimed: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Orbimed accounts for 8 tracked companies with verified cap-table data, 8 of which disclose round sizes totalling $2.3B. The median disclosed raise is $247M, and the largest is Miaoshou Doctor at $933M, ahead of Insilico Medicine ($416M) and Zhaoke Ophthalmology Pharmaceutical ($395M).

The names that recur most often on these portfolio cap tables are Orbimed (8 companies), Tencent (1 company), Sequoia Capital China (1 company), Warburg Pincus (1 company), Sequoia Capital (1 company), Mirae Asset Financial Group (1 company). By latest disclosed round, the market skews Series D (2), Series B (2), Series F (1), Series E (1).

Best funded Orbimed companies

  1. Miaoshou Doctor — $933M (latest: Series F)
  2. Insilico Medicine — $416M (latest: Series E)
  3. Zhaoke Ophthalmology Pharmaceutical — $395M (latest: IPO)
  4. InventisBio — $247M (latest: Series D)
  5. Evozyne — $144M (latest: Series B)
  6. Garuda Therapeutics — $72M (latest: Series A)
  7. ethris — $26M (latest: Series B)
  8. Affimed — $25M (latest: Series D)

Orbimed — related firms and companies (51)

Orbimed profile · All research reports